Philadelphia, April 2, 2014 – Clinical Therapeutics features a special report in its March issue focusing on the science and policy leading up to the US Food and Drug Administration's (FDA) preliminary steps toward restricting industrially produced trans fatty acids, or trans fat, at the federal level. "Trans fat is a compelling topic for Clinical Therapeutics to examine, because although it directly impacts human health, it also cues up controversy in multiple disciplines, including economics and politics," said John G. Ryan, Dr.PH., Topic Editor for Endocrinology and Diabetes, and guest editor for this multi-disciplinary investigation of trans fat.
Trans fat, derived from the partial hydrogenation of vegetable oils, is present in many processed foods and bakery items. The presence of trans fat in such foods is not always obvious, however, due to a 1999 FDA ruling (which became effective in 2006) that allows manufacturers to list the amount of fat per serving from trans fat as 0% if the actual amount per serving is below 0.5%. Scientific evidence linking various health risks with the consumption of trans fat formed the basis for a more recent ruling by the FDA. In the November 8, 2013 issue of the Federal Register, the FDA announced a preliminary ruling that trans fats are not generally recognized as safe (GRAS) for any use in food. This preliminary ruling, which proclaims partially hydrogenated oils as food additives, triggered a public comment period that ended on March 8, 2014.
Although the evidence linking trans fat with heart disease has mounted for years, the evolving science has at times been equivocal, largely because of two unique sources of trans fat: dietary and ruminant. "While there is an almost unanimous view that trans fatty acid should be phased out to less than 1% of total daily energy consumption, a similar consensus has not been reached with respect to TFA from ruminant meats and dairy since the amounts likely to be consumed are modest and outweighed by nutritional benefit," said Paul Nestel, M.D., professor of medicine and senior faculty at Baker IDI Heart and Diabetes Institute in Victoria, Australia, when asked about that evidence. Without federal action, local and state governments have stepped in to regulate trans fat. However, with the completion of the public comment period on March 8, the FDA will now review the evidence that dietary trans fat adversely impacts human health, resulting in a ruling about whether to restrict partially hydrogenated oils (PHOs) from the American diet, and by how much.
Federal regulation for protecting the public's health will likely have an impact on one or more stakeholders, such as the processed food and restaurant industries. The extent to which the impact of federal regulation will be costly, neutral or positive has yet to be determined. Joshua T. Cohen, Ph.D., deputy director of the Center for the Evaluation of Value and Risk in Health and a research associate professor of medicine at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, Boston, asserts that the benefit at the individual level is clearly positive. Dr. Cohen suggested recently that "a comparison of FDA's proposed regulation with other risks and with other measures to improve health reveals that it confers substantial individual benefits at a relatively low cost."
"Trans Fat, Regulation, Legislation and Human Health" includes papers by Dr. Nestel, Dr. Cohen, R. Rammy Assaf and Rishi Sood, MPH. Dr. Nestel describes the cumulative evidence linking TFA and cardiovascular disease while Dr. Cohen measures regulatory action by the FDA from a policy perspective. Mr. Assaf, a recent intern at the World Health Organization Health Systems and Services in Geneva, Switzerland, and a student at the University of Miami Miller School of Medicine, provides context for FDA action by describing the history of TFA regulations. Finally, Mr. Sood, health policy analyst, Bureau of Primary Care Access and Planning, New York City Department of Health and Mental Hygiene, describes the outcome of a voluntary TFA ban in Nassau County, NY. Dr. Ryan, Associate Professor and Director, Division of Primary Care/Health Services Research and Development in the Department of Family Medicine and Community Health at the University of Miami Miller School of Medicine, and Clinical Therapeutic Topic Editor for Endocrinology, Diabetes and Other Endocrine Disorders, summarizes the trans fatty acid debate in his editorial, "No Longer Generally Recognized As Safe ('GRAS')".
Full text of these articles is available to credentialed journalists upon request. Contact Executive Publisher Terry Materese at +1 215 239 3196 or firstname.lastname@example.org for copies. Journalists wishing to interview the authors should contact Dr. Marina Paul, at +1 215 239 3735 or email@example.com.
About Clinical Therapeutics
Clinical Therapeutics, an Elsevier publication, is dedicated to the rapid translation of reliable and evolving clinical and health services research into medical practice for an international audience of clinicians and scientists. Each issue of Clinical Therapeutics features a special themed section ("Update") comprised of original research articles, research letters, case reports, reviews, editorials, and video summaries that highlights new or controversial research within one of the journal's areas of expertise. Clinical Therapeutics Updates can be freely accessed at the journal's website: http://www.clinicaltherapeutics.com/content/SpecialFocus
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Tel: +1 215 239 3196
Cell: +1 215 327 9934
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.